Measuring Influenza Neutralizing Antibody Responses to A(H3N2) Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells
November 22nd, 2017
18K views
Influenza neutralizing antibodies correlate with protection of influenza infections. Microneutralization assays measure neutralizing antibodies in human sera and are often used for influenza human serology. We describe a microneutralization assay using MDCK-SIAT1 cells to measure neutralizing antibody titers to contemporary 3C.2a and 3C.3a A(H3N2) viruses following influenza vaccination or infection.
Overview
This article describes a microneutralization assay using MDCK-SIAT1 cells to measure neutralizing antibody responses to contemporary H3N2 influenza viruses. The assay is crucial for evaluating influenza immunity following vaccination or infection.
Key Study Components
Area of Science
- Immunology
- Virology
- Serology
Background
- Influenza neutralizing antibodies are critical for protection against infections.
- Microneutralization assays are commonly used to assess these antibodies in human sera.
- MDCK-SIAT1 cells are utilized for their effectiveness in detecting antibody responses.
- Understanding antibody responses helps in evaluating the efficacy of influenza vaccines.
Purpose of Study
- To measure neutralizing antibody titers to H3N2 influenza viruses.
- To determine the effectiveness of influenza vaccination in inducing protective antibody responses.
- To assess the ability of the assay to detect responses to circulating H3N2 strains.
Methods Used
- Propagation of H3N2 viruses in MDCK-SIAT1 cells.
- Microneutralization assays to measure antibody responses.
- Evaluation of neutralizing antibody titers in human sera.
- Comparison of responses post-vaccination and post-infection.
Main Results
- The assay successfully measures neutralizing antibody responses.
- Vaccination induces sufficient antibody responses against circulating strains.
- MDCK-SIAT1 cells provide a reliable platform for these assays.
- Results contribute to understanding influenza immunity.
Conclusions
- The microneutralization assay is effective for evaluating influenza immunity.
- It can help inform vaccine strategies against H3N2 influenza viruses.
- Further studies may enhance understanding of antibody responses over time.
Frequently Asked Questions
What is the purpose of the microneutralization assay?
The assay measures neutralizing antibody responses to H3N2 influenza viruses in human sera.
Why are MDCK-SIAT1 cells used in this assay?
MDCK-SIAT1 cells are effective for detecting antibody responses to influenza viruses.
How does vaccination affect neutralizing antibody responses?
Vaccination can induce sufficient neutralizing antibody responses to protect against circulating H3N2 strains.
What are the main advantages of this assay?
It utilizes a reliable cell line and provides insights into influenza immunity.
Can this assay be used for other influenza strains?
While focused on H3N2, the methodology may be adapted for other strains.
What are the implications of the study results?
The results can inform vaccine development and strategies against influenza.
Executive Industry Relevance
Accurate measurement of neutralizing antibody titers is essential for evaluating influenza vaccine efficacy and informing strain selection in biopharma R&D. The use of MDCK-SIAT1 cells improves assay sensitivity for contemporary A(H3N2) viruses with altered receptor binding, enhancing predictive confidence in immunogenicity data. This supports go/no-go decisions in preclinical and clinical vaccine development by providing quantitative, reproducible readouts of functional immunity.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional validation of hemagglutinin as a target by measuring antibody-mediated neutralization of viral infectivity.
- Operational Value: Provides a quantitative assay format to compare immune responses across vaccine candidates or viral strains.
Screening & Assay Development
- Scientific Value: Generates dose-response data from serial serum dilutions to calculate IC50-equivalent neutralizing titers.
- Operational Value: Standardizes virus-antibody incubation and infection steps using MDCK-SIAT1 cells for improved assay robustness with drifted H3N2 strains.
- Scientific Value: ELISA-based detection of viral nucleoprotein offers a specific, quantitative readout of infection levels post-neutralization.
Translational & Preclinical Research
- Scientific Value: Supports translational bridge from human serology to preclinical models by defining protective titer thresholds.
- Operational Value: Enables longitudinal assessment of antibody responses in vaccine studies to inform dosing and schedule optimization.
Pipeline & Workflow Integration
The assay fits within the immunogenicity evaluation workflow following antigen expression and purification, serving as a functional readout prior to challenge models or clinical correlation studies.
- Discovery Biology: Measures functional antibody activity to validate immunological relevance of HA-targeted vaccine candidates.
- Screening: Delivers reproducible neutralization titers to rank immunogenicity of vaccine formulations against drifted H3N2 strains.
- Analytics: Outputs OD-based infection metrics analyzed via Reed-Muench to derive TCID50 and neutralizing titers with defined 50% cutoff criteria.
- Translational Research: Connects in vitro neutralization data to clinical protection estimates through established correlates of immunity.
- Enterprise Reuse: Platform can be adapted for other influenza subtypes by updating virus strain and maintaining MDCK-SIAT1 cell substrate for sialic acid-dependent strains.
Operational & Enterprise Impact
- Scientific Value: Reduces false-negative results in antibody screening by improving viral infectivity in assay systems for antigenically drifted H3N2.
- Operational Value: Increases assay consistency through standardized virus titration (100 TCID50/well) and defined incubation parameters (18–20 h, 37°C, 5% CO2).
- Strategic Value: Supports risk-adjusted advancement of vaccine candidates by providing early, quantitative immunogenicity data linked to protection.
- Portfolio Impact: Enables cross-strain comparison of vaccine-induced responses to guide strain selection in multivalent or updated vaccine design.
Implementation Considerations
- Requires expertise in virology for safe handling and titration of influenza virus stocks.
- Dependent on access to MDCK-SIAT1 cells and biosafety level 2 infrastructure for virus propagation and assay execution.
- Necessitates standardized reagents including anti-NP monoclonal antibodies and substrate systems for ELISA detection.
- Requires optimization when extending to influenza subtypes with differing receptor binding preferences.
- Subject to variability in serum heat inactivation and pre-dilution steps that must be controlled for reproducibility.
Biopharma FAQs
Why does neutralization threshold setting matter for antibody titer calculation?
The 50% neutralization cutoff is defined as the average of virus control and cell control optical densities, establishing a consistent threshold to determine the highest serum dilution that inhibits infection. This ensures reproducible titer calculations across experiments and laboratories.
How does virus titration at 100 TCID50/well support assay standardization?
Using a fixed virus input of 100 TCID50 per well ensures consistent infection challenge across conditions, enabling reliable comparison of antibody-mediated inhibition. This standardization is critical for accurate titer determination and inter-assay comparability.
What enables quantitative measurement of virus infection after antibody neutralization?
Virus infection is quantified by ELISA using anti-influenza A nucleoprotein antibodies, which detect intracellular viral protein levels proportional to infection. This provides a specific, measurable signal to calculate neutralization percentages.
Why are replication requirements important for assay validation across laboratories?
Replicate wells and repeated experiments are necessary to confirm assay precision and reproducibility, especially when measuring subtle differences in antibody titers. This supports reliable data for vaccine evaluation and regulatory submissions.
What statistical method is used to calculate virus titer from ELISA data?
The Reed-Muench method is used to calculate TCID50 from optical density readings across virus dilutions, establishing the infectious units per milliliter. This underpins the standardization of virus input in neutralization assays.
Chapters in this video
0:05
Title
1:09
Determination of Tissue-culture Infectious Dose (TCID) of the Virus
5:44
Microneutralization (MN) Assay Using MDCK-SIAT1 Cells
9:44
Results: Microneutralization Assay Results of Human Sera tested Against A/HongKong/4801/2014 A(H3N2) Virus Using MDCK-SIAT1 Cells
11:25
Conclusion
